150 related articles for article (PubMed ID: 8809644)
1. Clearance of phenytoin and valproic acid is affected by a small body weight reduction in an epileptic obese patient: a case study.
Kuranari M; Chiba S; Ashikari Y; Kodama Y; Sakata T; Takeyama M
J Clin Pharm Ther; 1996 Apr; 21(2):83-7. PubMed ID: 8809644
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic interactions of valproate, phenytoin, phenobarbitone and carbamazepine with curcumin in experimental models of epilepsy in rats.
Reeta KH; Mehla J; Pahuja M; Gupta YK
Pharmacol Biochem Behav; 2011 Sep; 99(3):399-407. PubMed ID: 21641922
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of fluorescence polarization assays for measuring valproic acid, phenytoin, carbamazepine and phenobarbital in serum.
Steijns LS; Bouw J; van der Weide J
Ther Drug Monit; 2002 Jun; 24(3):432-5. PubMed ID: 12021637
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data.
Jiao Z; Shi XJ; Zhao ZG; Zhong MK
J Clin Pharm Ther; 2004 Jun; 29(3):247-56. PubMed ID: 15153086
[TBL] [Abstract][Full Text] [Related]
5. Estimation of apparent clearance of valproic acid in adult Saudi patients.
Alqahtani S; Alandas N; Alsultan A
Int J Clin Pharm; 2019 Aug; 41(4):1056-1061. PubMed ID: 31222537
[TBL] [Abstract][Full Text] [Related]
6. Rapid anti-epileptic drug assay.
Cosgrove M; Pople S; Wallace SJ
Dev Med Child Neurol; 1990 Sep; 32(9):796-9. PubMed ID: 2227143
[TBL] [Abstract][Full Text] [Related]
7. Investigation of phenobarbital-carbamazepine-valproic acid interactions using population pharmacokinetic analysis for optimisation of antiepileptic drug therapy: an overview.
Yukawa E
Drug Metabol Drug Interact; 2000; 16(2):86-98. PubMed ID: 10962642
[TBL] [Abstract][Full Text] [Related]
8. Isobolographic analysis of interactions between remacemide and conventional antiepileptic drugs in the mouse model of maximal electroshock.
Borowicz KK; Malek R; Luszczki JJ; Ratnaraj N; Patsalos PN; Czuczwar SJ
Epilepsy Behav; 2007 Aug; 11(1):6-12. PubMed ID: 17602881
[TBL] [Abstract][Full Text] [Related]
9. [Effects of antiepileptic drugs on delivery and early childhood--comparison among mono-therapies of valproic acid, phenytoin, carbamazepine and phenobarbital].
Tanaka H; Takeda A; Izumi M; Okada H; Ishikawa S
Rinsho Shinkeigaku; 1991 Mar; 31(3):266-9. PubMed ID: 1893664
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interactions among phenobarbital, carbamazepine, and valproic acid in pediatric Japanese patients: clinical considerations on steady-state serum concentration-dose ratios.
Yukawa E; Hokazono T; Satou M; Ohdo S; Higuchi S; Aoyama T
Am J Ther; 2000 Sep; 7(5):303-8. PubMed ID: 11317175
[TBL] [Abstract][Full Text] [Related]
11. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics.
Yukawa E; To H; Ohdo S; Higuchi S; Aoyama T
J Clin Pharmacol; 1997 Dec; 37(12):1160-7. PubMed ID: 9506012
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis.
Bae EK; Lee J; Shin JW; Moon J; Lee KJ; Shin YW; Kim TJ; Shin D; Jang IJ; Lee SK
Seizure; 2016 Apr; 37():8-12. PubMed ID: 26908152
[TBL] [Abstract][Full Text] [Related]
13. A model for estimating individualized valproate clearance values in children.
Botha JH; Gray AL; Miller R
J Clin Pharmacol; 1995 Oct; 35(10):1020-4. PubMed ID: 8568010
[TBL] [Abstract][Full Text] [Related]
14. Established antiepileptic drugs.
Perucca E
Baillieres Clin Neurol; 1996 Dec; 5(4):693-722. PubMed ID: 9068876
[TBL] [Abstract][Full Text] [Related]
15. Effect of CYP3A5 genotypes on the pharmacokinetics of carbamazepine when used as monotherapy or co-administered with phenytoin, phenobarbital or valproic acid in Thai patients.
Panomvana D; Traiyawong T; Towanabut S
J Pharm Pharm Sci; 2013; 16(4):502-10. PubMed ID: 24210059
[TBL] [Abstract][Full Text] [Related]
16. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data.
Blanco-Serrano B; Otero MJ; Santos-Buelga D; García-Sánchez MJ; Serrano J; Domínguez-Gil A
Biopharm Drug Dispos; 1999 Jul; 20(5):233-40. PubMed ID: 10594867
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation.
Glue P; Banfield CR; Perhach JL; Mather GG; Racha JK; Levy RH
Clin Pharmacokinet; 1997 Sep; 33(3):214-24. PubMed ID: 9314612
[TBL] [Abstract][Full Text] [Related]
18. Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening.
Yukawa E; Honda T; Ohdo S; Higuchi S; Aoyama T
J Pharm Pharmacol; 1997 Aug; 49(8):751-6. PubMed ID: 9379350
[TBL] [Abstract][Full Text] [Related]
19. N-(anilinomethyl)-p-isopropoxyphenylsuccinimide potentiates the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock-induced seizure model.
Luszczki JJ; Kocharov SL; Czuczwar SJ
Neurosci Res; 2009 Jul; 64(3):267-72. PubMed ID: 19447295
[TBL] [Abstract][Full Text] [Related]
20. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.
Spina E; Pisani F; Perucca E
Clin Pharmacokinet; 1996 Sep; 31(3):198-214. PubMed ID: 8877250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
